UPDATE: JPMorgan Downgrades ObsEva (OBSV) to Underweight on Continued Cash Woes into PRIMROSE Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. CRWV
8. CME
9. HUMA
10. NVDA

Go back to UPDATE: JPMorgan Downgrades ObsEva (OBSV) to Underweight on Continued Cash Woes into PRIMROSE Update

ObsEva SA (OBSV) Announces Brian O’Callaghan as CEO

November 9, 2020 5:53 AM EST

ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health today announced that ObsEvas Board of Directors has appointed Brian OCallaghan, to succeed Dr Ernest Loumaye, as Chief Executive Officer and member of the companys Executive Committee, effective 1 December 2020. He will also be proposed for election on ObsEvas Board of Directors at next company AGM.

As ObsEva evolves from a development company towards commercialization, Dr Ernest Loumaye, co-founder and CEO of ObsEva, has expressed his wish to... More